Clinical Trials Logo
  1. Home
  2. Leprosy
  3. NCT03302897

Phase 1 LEP-F1 + GLA-SE Vaccine Trial in Healthy Adult Volunteers

Leprosy Clinical Trial

Official title:
A Phase 1, Open Label, Antigen Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of LEP-F1 + GLA-SE in Healthy Adult Subjects

Clinical Trial Summary

The purpose of this study is to compare the safety, tolerability, and immunogenicity in healthy adult subjects of an investigational vaccine being developed for the prevention of leprosy. Two dose levels of the vaccine will be evaluated.

Clinical Trial Description

The purpose of this study is to compare the safety, tolerability, and immunogenicity of the LEP-F1 + GLA-SE vaccine. The vaccine consists of the recombinant four-antigen Mycobacterium leprae antigen LEP-F1 in combination with the adjuvant formulation GLA-SE (Glucopyranosyl Lipid A - Stable Emulsion) and is being developed for the prevention of leprosy disease. This is a first-in-human study and will be conducted in healthy adult subjects. Two dose levels of the vaccine (2 μg LEP-F1 + 5 μg GLA-SE and 10 μg LEP-F1 + 5 μg GLA-SE) will be given by intramuscular administration on study Days 0, 28, and 56. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03302897
Study type Interventional
Source IDRI
Contact
Status Completed
Phase Phase 1
Start date October 2, 2017
Completion date March 5, 2019
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05243654 - Efficacy and Tolerability of Adjunct Metformin for Multibacillary Leprosy Phase 2
Completed NCT05091216 - The Effects of Traditional Chinese Medicine Mouthwash Solutions on the Oral Health of Leprosy Patients N/A
Completed NCT00860717 - The Use of Low Level Laser Therapy for Wound Healing in Leprosy Patients N/A
Recruiting NCT06222372 - Novel Interventions and Diagnostic Tests for Leprosy N/A
Terminated NCT03084614 - CD8 Reactivity to Microorganisms in Blood and Breast Milk
Recruiting NCT05597280 - Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy Phase 3
Terminated NCT01751503 - Extramembranous and Interosseous Technique of Tibialis Posterior Tendon Transfer N/A
Active, not recruiting NCT03324035 - Treatment of Neuropathic Pain in Leprosy Phase 3
Recruiting NCT03683745 - Integrated Mapping of Skin-presenting Neglected Tropical Diseases in Liberia
Recruiting NCT02550080 - Clinical Utility Of Genetic Screening For HLA-B*1301, On Susceptibility To Dapsone Hypersensitivity Syndrome Phase 4
Completed NCT02484469 - Impact of the Virtual Human Project on Team-based Learning: A Randomized-controlled Trial N/A
Completed NCT00919542 - Ciclosporin in the Management of New Erythema Nodosum Leprosum Phase 2
Completed NCT01165840 - Effect of Weight and/or Obesity on Dapsone Drug Concentrations Phase 4
Completed NCT05406479 - Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy (Phase 2) Phase 2
Recruiting NCT03807362 - CC-11050 Trial in Nepalese Patients With Erythema Nodosum Leprosum Phase 2
Completed NCT01006759 - Prevention of Disability: Proposal for a Guidance Manual for Leprosy Patients Phase 1
Completed NCT03662022 - Post ExpOsure Prophylaxis for LEprosy in the Comoros and Madagascar Phase 3
Completed NCT01920750 - Leprosy Skin Test Antigens Phase 1 Phase 1
Not yet recruiting NCT03947437 - Phase 1b/2a Trial to Evaluate LEP-F1 + GLA-SE in Healthy Adults and Leprosy Patients Phase 1/Phase 2
Completed NCT00669643 - Uniform Multidrug Therapy Regimen for Leprosy Patients Phase 4